CASTLE BIOSCIENCES INC (CSTL) Stock Fundamental Analysis
USA - NASDAQ:CSTL - US14843C1053 - Common Stock
22.53 USD
+0.02 (+0.09%)
22.53 USD
0 (0%)
Overall CSTL gets a fundamental rating of 4 out of 10. We evaluated CSTL against 100 industry peers in the Health Care Providers & Services industry. CSTL has a great financial health rating, but its profitability evaluates not so good. CSTL is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
CSTL had positive earnings in the past year.
In the past year CSTL had a positive cash flow from operations.
In the past 5 years CSTL reported 4 times negative net income.
In multiple years CSTL reported negative operating cash flow during the last 5 years.
1.2 Ratios
With a Return On Assets value of -1.74%, CSTL is not doing good in the industry: 60.00% of the companies in the same industry are doing better.
CSTL has a Return On Equity of -2.08%. This is comparable to the rest of the industry: CSTL outperforms 48.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.74% | ||
| ROE | -2.08% | ||
| ROIC | N/A |
ROA(3y)-8.08%
ROA(5y)-6.67%
ROE(3y)-9.16%
ROE(5y)-7.51%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CSTL's Profit Margin has been stable in the last couple of years.
In the last couple of years the Operating Margin of CSTL has declined.
CSTL has a better Gross Margin (81.00%) than 94.00% of its industry peers.
In the last couple of years the Gross Margin of CSTL has remained more or less at the same level.
CSTL does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 81% |
OM growth 3YN/A
OM growth 5Y-28.6%
PM growth 3YN/A
PM growth 5Y-1.01%
GM growth 3Y-0.54%
GM growth 5Y-0.96%
2. Health
2.1 Basic Checks
CSTL does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CSTL has been increased compared to 1 year ago.
Compared to 5 years ago, CSTL has more shares outstanding
Compared to 1 year ago, CSTL has a worse debt to assets ratio.
2.2 Solvency
CSTL has an Altman-Z score of 4.97. This indicates that CSTL is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 4.97, CSTL is in the better half of the industry, outperforming 80.00% of the companies in the same industry.
The Debt to FCF ratio of CSTL is 0.30, which is an excellent value as it means it would take CSTL, only 0.30 years of fcf income to pay off all of its debts.
CSTL has a Debt to FCF ratio of 0.30. This is amongst the best in the industry. CSTL outperforms 93.00% of its industry peers.
A Debt/Equity ratio of 0.02 indicates that CSTL is not too dependend on debt financing.
CSTL has a Debt to Equity ratio of 0.02. This is amongst the best in the industry. CSTL outperforms 83.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.3 | ||
| Altman-Z | 4.97 |
ROIC/WACCN/A
WACC8.68%
2.3 Liquidity
A Current Ratio of 6.85 indicates that CSTL has no problem at all paying its short term obligations.
CSTL's Current ratio of 6.85 is amongst the best of the industry. CSTL outperforms 96.00% of its industry peers.
A Quick Ratio of 6.69 indicates that CSTL has no problem at all paying its short term obligations.
CSTL has a better Quick ratio (6.69) than 96.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.85 | ||
| Quick Ratio | 6.69 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 357.14% over the past year.
Measured over the past years, CSTL shows a very strong growth in Earnings Per Share. The EPS has been growing by 29.69% on average per year.
The Revenue has grown by 20.41% in the past year. This is a very strong growth!
The Revenue has been growing by 44.95% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)357.14%
EPS 3YN/A
EPS 5Y29.69%
EPS Q2Q%-51.61%
Revenue 1Y (TTM)20.41%
Revenue growth 3Y52.25%
Revenue growth 5Y44.95%
Sales Q2Q%-0.94%
3.2 Future
CSTL is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -31.41% yearly.
Based on estimates for the next years, CSTL will show a small growth in Revenue. The Revenue will grow by 4.62% on average per year.
EPS Next Y-395.59%
EPS Next 2Y-123.77%
EPS Next 3Y-70.43%
EPS Next 5Y-31.41%
Revenue Next Year-3.02%
Revenue Next 2Y-2.15%
Revenue Next 3Y1.44%
Revenue Next 5Y4.62%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
CSTL is valuated quite expensively with a Price/Earnings ratio of 62.58.
The rest of the industry has a similar Price/Earnings ratio as CSTL.
The average S&P500 Price/Earnings ratio is at 27.31. CSTL is valued rather expensively when compared to this.
The Forward Price/Earnings Ratio is negative for CSTL. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 62.58 | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, CSTL is valued a bit cheaper than the industry average as 71.00% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, CSTL is valued a bit cheaper than the industry average as 67.00% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 18.92 | ||
| EV/EBITDA | 9.97 |
4.3 Compensation for Growth
CSTL's earnings are expected to decrease with -70.43% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)2.11
EPS Next 2Y-123.77%
EPS Next 3Y-70.43%
5. Dividend
5.1 Amount
CSTL does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
22.53
+0.02 (+0.09%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners93.13%
Inst Owner Change0%
Ins Owners2.7%
Ins Owner Change1.77%
Market Cap653.60M
Analysts88.57
Price Target36.34 (61.3%)
Short Float %6.37%
Short Ratio3.41
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-23.82%
Min EPS beat(2)-175.74%
Max EPS beat(2)128.1%
EPS beat(4)3
Avg EPS beat(4)183.56%
Min EPS beat(4)-175.74%
Max EPS beat(4)558.79%
EPS beat(8)7
Avg EPS beat(8)146.14%
EPS beat(12)10
Avg EPS beat(12)99.67%
EPS beat(16)12
Avg EPS beat(16)80.49%
Revenue beat(2)2
Avg Revenue beat(2)12.85%
Min Revenue beat(2)7.37%
Max Revenue beat(2)18.34%
Revenue beat(4)4
Avg Revenue beat(4)8.59%
Min Revenue beat(4)3.31%
Max Revenue beat(4)18.34%
Revenue beat(8)8
Avg Revenue beat(8)13.11%
Revenue beat(12)12
Avg Revenue beat(12)10.99%
Revenue beat(16)16
Avg Revenue beat(16)10.02%
PT rev (1m)0%
PT rev (3m)-0.74%
EPS NQ rev (1m)0%
EPS NQ rev (3m)16.27%
EPS NY rev (1m)0%
EPS NY rev (3m)23.37%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)6.49%
Revenue NY rev (1m)0%
Revenue NY rev (3m)7.99%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 62.58 | ||
| Fwd PE | N/A | ||
| P/S | 1.89 | ||
| P/FCF | 18.92 | ||
| P/OCF | 10.46 | ||
| P/B | 1.44 | ||
| P/tB | 1.86 | ||
| EV/EBITDA | 9.97 |
EPS(TTM)0.36
EY1.6%
EPS(NY)-1.89
Fwd EYN/A
FCF(TTM)1.19
FCFY5.28%
OCF(TTM)2.15
OCFY9.56%
SpS11.94
BVpS15.7
TBVpS12.11
PEG (NY)N/A
PEG (5Y)2.11
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.74% | ||
| ROE | -2.08% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 81% | ||
| FCFM | 9.97% |
ROA(3y)-8.08%
ROA(5y)-6.67%
ROE(3y)-9.16%
ROE(5y)-7.51%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5Y-28.6%
PM growth 3YN/A
PM growth 5Y-1.01%
GM growth 3Y-0.54%
GM growth 5Y-0.96%
F-Score4
Asset Turnover0.64
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.3 | ||
| Debt/EBITDA | 0.44 | ||
| Cap/Depr | 65.78% | ||
| Cap/Sales | 8.07% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 321.49% | ||
| Profit Quality | N/A | ||
| Current Ratio | 6.85 | ||
| Quick Ratio | 6.69 | ||
| Altman-Z | 4.97 |
F-Score4
WACC8.68%
ROIC/WACCN/A
Cap/Depr(3y)113.65%
Cap/Depr(5y)290.73%
Cap/Sales(3y)6.28%
Cap/Sales(5y)6.02%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)357.14%
EPS 3YN/A
EPS 5Y29.69%
EPS Q2Q%-51.61%
EPS Next Y-395.59%
EPS Next 2Y-123.77%
EPS Next 3Y-70.43%
EPS Next 5Y-31.41%
Revenue 1Y (TTM)20.41%
Revenue growth 3Y52.25%
Revenue growth 5Y44.95%
Sales Q2Q%-0.94%
Revenue Next Year-3.02%
Revenue Next 2Y-2.15%
Revenue Next 3Y1.44%
Revenue Next 5Y4.62%
EBIT growth 1Y-46.28%
EBIT growth 3YN/A
EBIT growth 5Y3.5%
EBIT Next Year330.52%
EBIT Next 3Y-140.1%
EBIT Next 5Y-26.67%
FCF growth 1Y166.87%
FCF growth 3YN/A
FCF growth 5Y43.14%
OCF growth 1Y254.44%
OCF growth 3YN/A
OCF growth 5Y56%